Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Apalutamide is a second-generation highly selective androgen receptor antagonist, and its affinity with androgen receptors is more than 5 times that of the first-generation androgen receptor antagonists. A phase III study involving 1207 patients with non-metastatic castration-resistant prostate cancer demonstrated that apalutamide significantly prolonged metastasis-free survival (40.5 vs 16.2 months) compared with placebo. 2018/2/14, Apalutamide was approved by the FDA for the treatment of non-metastatic (prostate cancer cells have not spread) castration-resistant prostate cancer (the disease still progresses after hormone therapy)